Research Analysts Set Expectations for FOLD Q4 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Stock analysts at Leerink Partnrs lifted their Q4 2024 earnings estimates for Amicus Therapeutics in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($0.03) per share for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q1 2025 earnings at ($0.05) EPS.

A number of other analysts have also recently issued reports on FOLD. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Bank of America boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Trading Up 0.3 %

Shares of FOLD opened at $9.54 on Wednesday. The stock’s 50-day moving average price is $9.64 and its 200 day moving average price is $10.52. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics has a 12-month low of $8.78 and a 12-month high of $14.03. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of -28.06, a P/E/G ratio of 1.51 and a beta of 0.62.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in FOLD. Wellington Management Group LLP grew its holdings in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after acquiring an additional 2,856,101 shares during the last quarter. Millennium Management LLC lifted its position in shares of Amicus Therapeutics by 1,758.9% during the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock worth $18,790,000 after purchasing an additional 1,792,277 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $13,530,000. Assenagon Asset Management S.A. increased its holdings in shares of Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after purchasing an additional 1,192,489 shares in the last quarter. Finally, Squarepoint Ops LLC raised its position in Amicus Therapeutics by 159.1% in the 2nd quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company’s stock worth $6,454,000 after purchasing an additional 399,449 shares during the last quarter.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $11.46, for a total value of $85,950.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 22,901 shares of company stock valued at $259,863. 2.20% of the stock is currently owned by insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.